Sign up
Quantellect · Analysts · Analyst Profile
Analyst Score Rank#564 of 589

Aydin Huseynov

Ladenburg Thalmann · Equity Research Analyst
ProvisionalRating since 2022No new ratings since Oct 2025

Analyst rating accuracy & track record

Aydin Huseynov is an equity research analyst at Ladenburg Thalmann. Quantellect has scored 26 of their stock calls across 17 companies. Their picks beat their sector 32% of the time over the next 12 months, and their price targets were reached 29% of the time within a year.

Win % vs sector
32%
PT Hit % (12mo)
29%
Avg sector-excess
−27.1%
Scored calls
26
Tickers
17
Tier
Provisional

Track record

Quantellect has scored 26 of Aydin Huseynov's stock calls across 17 companies, dating back to 2022. Their rated stocks beat their own sector 32% of the time over the next 12 months. On a typical call, a Huseynov pick returned −27.1% more than its sector over the following year.

Of the scored calls, 26 were bullish (Buy). Most of their coverage sits in Healthcare. Every number on this page is an estimate from our own data. It is for education only and is not investment advice.

Coverage & ratings

Ratings & price targets

StockRatingPrice targetRated12-mo vs sectorPT hit
IMUXImmunic Inc
Buy$30.00Oct 2025−37.2%Miss
IMUXImmunic Inc
Buy$30.00Oct 2025−37.2%Miss
KALAKala Pharmaceuticals Inc
Buy$12.00Jul 2025−120.7%Hit
KALAKala Pharmaceuticals Inc
Buy$600.00Jul 2025−120.7%Miss
ARDXArdelyx Inc
Buy$11.00Mar 2025+11.4%Miss
URGNUroGen Pharma Ltd
Buy$31.00Feb 2025+94.8%Miss
MRKRMarker Therapeutics Inc
Buy$19.00Oct 2024−74.9%Miss
CRVSCorvus Pharmaceuticals Inc
Buy$21.00Sep 2024+14.9%Miss
ACRVAcrivon Therapeutics, Inc. Common Stock
Buy$16.00Sep 2024−69.1%Miss
CLDICalidi Biotherapeutics Inc.
Buy$1.00Jun 2024−82.3%Hit
MRKRMarker Therapeutics Inc
Buy$11.00Apr 2024−72.6%Miss
RNTXRein Therapeutics Inc
Buy$19.00Apr 2024−59.4%Miss
ACRVAcrivon Therapeutics, Inc. Common Stock
Buy$14.00Apr 2024−72.2%Miss
BDRXBiodexa Pharmaceticals
Buy$8.00Feb 2024−90.9%Miss
PMVPPmv Pharmaceuticals Inc
Buy$7.00Dec 2023−56.5%Miss
RNTXRein Therapeutics Inc
Buy$9.00Dec 2023+4.6%Miss
ATHEAlterity Therapeutics Ltd
Buy$10.00Jun 2023−45.8%Miss
CRVSCorvus Pharmaceuticals Inc
Buy$10.00May 2023−43.5%Miss
PALIPalisade Bio Inc
Buy$16.00May 2023−87.0%Miss
TPSTTempest Therapeutics Inc
Buy$14.00Apr 2023+50.0%Miss
CRVSCorvus Pharmaceuticals Inc
Buy$2.00Oct 2022+49.6%Hit
TPSTTempest Therapeutics Inc
Buy$8.00Sep 2022−84.1%Miss
ATHEAlterity Therapeutics Ltd
Buy$2.00Aug 2022−60.1%Miss
ANEBAnebulo Pharmaceuticals Inc
Buy$6.00Jul 2022−26.3%Miss
NVCTNuvectis Pharma Inc
Buy$21.00Jul 2022+28.3%Miss
Prev1
Go to

Aydin Huseynov: analyst track record FAQ

Is Aydin Huseynov a good stock analyst?

Yes, by track record. Aydin Huseynov ranks number 564 of 589 of the analysts Quantellect scores, with an Analyst Score of 0 out of 100. Past results do not guarantee future ones.

What is Aydin Huseynov's win rate?

Aydin Huseynov's win rate is 32%. Across 26 scored calls, their rated stocks beat their sector 32% of the time over the next 12 months. On a typical call they returned −27.1% more than the sector.

What stocks and sectors does Aydin Huseynov cover?

Aydin Huseynov covers 17 companies, with the most coverage in Healthcare. See the ratings table above for every scored call and its outcome.

Are Aydin Huseynov's price targets accurate?

Aydin Huseynov's price targets are reached within 12 months 29% of the time. The base rate across all analysts Quantellect tracks is about 43 percent.

How accurate are Wall Street analyst price targets?

Most analyst price targets are not reached on schedule. Across every target Quantellect scores, the stock reaches the target within 12 months only about 43 percent of the time, which is why it helps to compare hit rates analyst by analyst.

Should I follow Aydin Huseynov's stock ratings?

Their track record is strong, but no analyst is right every time. Follow the long-term track record rather than any single rating, size your positions to your own risk, and treat this as research, not investment advice.

How does Quantellect score analyst accuracy?

Quantellect scores every rating on real prices. We enter at the closing price on or after the call date, with no look-ahead, then measure the 12-month return above the stock's sector ETF and check whether the price target was reached. Scores are pulled toward the population average and corrected for testing thousands of analysts at once, so they reflect repeatable skill rather than luck.

How does Aydin Huseynov rank among Wall Street analysts?

Aydin Huseynov ranks number 564 of 589 by Analyst Score. We rank analysts by their realized 12-month sector-excess return and require a minimum number of calls so a few lucky picks cannot reach the top.

Browse the full analyst leaderboardHow analyst accuracy is scored

Every score, Win %, PT Hit % and rank is an estimate Quantellect calculates from its own data and may not be 100% accurate or complete. Returns are measured in excess of each rated stock's own sector over the 12 months after each call. Past performance does not guarantee future results, and nothing here is a recommendation to buy or sell any security.